| Catalog No. | HB604016 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Chimeric |
|---|
| Isotype | IgG1-kappa |
|---|
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
CD105, END, Endoglin, ENG |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G purified from cell culture supernatant. |
| Accession |
P17813 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names | TRC-105, c-SN6j, 1268714-50-6 |
|---|
| Background | Carotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions.
• Endoglin Is an Important Mediator in the Final Common Pathway of Chronic Kidney Disease to End-Stage Renal Disease., PMID:36614087
• Microvascular endoglin (CD105) expression correlates with tissue markers for atherosclerotic plaque vulnerability in an ageing population with multivessel coronary artery disease., PMID:22463585
• Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining., PMID:15272276
• Antibody phage display technologies with special reference to angiogenesis., PMID:15746176
• Endoglin is necessary for angiogenesis in human ovarian carcinoma-derived primary endothelial cells., PMID:23917399
• Generation of a Soluble Form of Human Endoglin Fused to Green Fluorescent Protein., PMID:34681942
• Synovial biomarkers in psoriatic arthritis., PMID:22751595
• Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide., PMID:11691802
• A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma., PMID:27328856
• Elabela gene therapy promotes angiogenesis after myocardial infarction., PMID:34291565
|
|---|
| Note |
For research use only. Not suitable for clinical or therapeutic use. |
中文
English
